NCT05444530

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety of VAC85135 administered with ipilimumab for the treatment of myeloproliferative neoplasms (MPNs).

Conditions

• Myeloproliferative Neoplasms

Interventions

Type	Name	Description
BIOLOGICAL	VAC85135	Participants will receive VAC85135 as IM injection.
DRUG	Ipilimumab	Participants will receive Ipilimumab as IV infusion.

Timeline

• Start date: 2022-07-21
• Primary completion: 2025-06-24
• Completion: 2025-06-24
• First posted: 2022-07-06
• Last updated: 2025-07-20

Locations

7 sites across 2 countries: United States, United Kingdom

Regulatory

• FDA-regulated drug study